Vaughn Himes - Jun 7, 2023 Form 4 Insider Report for Seagen Inc. (SGEN)

Signature
By: /s/ Jennifer Prosba For: Vaughn B Himes
Stock symbol
SGEN
Transactions as of
Jun 7, 2023
Transactions value $
-$2,501,107
Form type
4
Date filed
6/9/2023, 06:50 PM
Previous filing
May 3, 2023
Next filing
Jul 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SGEN Common Stock Options Exercise $665K +16.2K +36.99% $41.04 60.1K Jun 7, 2023 Direct F1
transaction SGEN Common Stock Sale -$3.17M -16.2K -27% $195.29 43.8K Jun 7, 2023 Direct F1, F2, F3
holding SGEN Common Stock 119K Jun 7, 2023 by Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGEN Non-Qualified Stock Option (right to buy) Options Exercise $0 -16.2K -100% $0.00* 0 Jun 7, 2023 Common Stock 16.2K $41.04 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
F2 The sales reported in this Form 4 were effected pursuant to a written plan, entered into on November 29, 2022, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
F3 Reflects sales of common stock executed in multiple transactions at prices ranging from $195.00 to $195.60. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4 Options vested at a rate of 25% on 8/19/14 and monthly thereafter until all the options were fully vested on 8/19/17.